Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Spanish Breast Cancer Research Group
National Institutes of Health Clinical Center (CC)
Shandong Cancer Hospital and Institute
City of Hope Medical Center
Fudan University
Merck Sharp & Dohme LLC
University of Wisconsin, Madison
Haukeland University Hospital
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
European Institute of Oncology
University of Illinois at Chicago
University of Nebraska
Hebei Medical University Fourth Hospital
H. Lee Moffitt Cancer Center and Research Institute
The Netherlands Cancer Institute
University of Nebraska
University of Kansas Medical Center
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Karolinska University Hospital
Virginia Commonwealth University
Tanta University
Second Affiliated Hospital, School of Medicine, Zhejiang University
Thomas Jefferson University
Beth Israel Deaconess Medical Center
Baylor Breast Care Center
UNICANCER
European Institute of Oncology
Oslo University Hospital
Oslo University Hospital
The National Center of Oncology, Azerbaijan
The First Affiliated Hospital with Nanjing Medical University
RemeGen Co., Ltd.
Fudan University
Palleos Healthcare GmbH
Fundacao Champalimaud
RemeGen Co., Ltd.
National Institutes of Health Clinical Center (CC)
European Organisation for Research and Treatment of Cancer - EORTC
ETOP IBCSG Partners Foundation
Teva Branded Pharmaceutical Products R&D, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Haukeland University Hospital
University of Nebraska
Sun Yat-sen University
Indiana University
University of Nebraska